Acumen Pharmaceuticals completed the first closing a $20 million Series A funding round, which will be used to demonstrate proof of concept for the monoclonal antibody ACU-193 in the treatment of Alzheimer's disease by 2016.
Acumen raises $20m Series A for Alzheimer's antibody
Acumen Pharmaceuticals completed the first closing a $20 million Series A funding round, which will be used to demonstrate proof of concept for the monoclonal antibody ACU-193 in the treatment of Alzheimer's disease by 2016.
More from Neurological
More from Therapeutic Category
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.